1-10 of 10
Christian Weyer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity

Steve R. Smith, MD, Louis J. Aronne, MD, Colleen M. Burns, PHD, Nicole C. Kesty, PHD, Amy E. Halseth, PHD, Christian Weyer, MD
Journal: Diabetes Care
Diabetes Care 2008;31(9):1816–1823
https://doi.org/10.2337/dc08-0029
Published: 01 September 2008
View article titled, Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity
Open the PDF for Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity in another window
Includes: Supplementary data
Journal Articles

Effects of Pramlintide on Postprandial Glucose Excursions and Measures of Oxidative Stress in Patients With Type 1 Diabetes

Antonio Ceriello, MD, Ludovica Piconi, PHD, Lisa Quagliaro, PHD, Yan Wang, PHD, Catherine A. Schnabel, PHD, James A. Ruggles, PHD, Maurice A. Gloster, MD, David G. Maggs, MD, Christian Weyer, MD
Journal: Diabetes Care
Diabetes Care 2005;28(3):632–637
https://doi.org/10.2337/diacare.28.3.632
Published: 01 March 2005
View article titled, Effects of Pramlintide on Postprandial Glucose Excursions and Measures of Oxidative Stress in Patients With Type 1 Diabetes
Open the PDF for Effects of Pramlintide on Postprandial Glucose Excursions and Measures of Oxidative Stress in Patients With Type 1 Diabetes in another window
Journal Articles

Plasma Adiponectin and Endogenous Glucose Production in Humans

Norbert Stefan, MD, Michael Stumvoll, MD, Barbora Vozarova, MD, Christian Weyer, MD, Tohru Funahashi, MD, PHD, Yuji Matsuzawa, MD, PHD, Clifton Bogardus, MD, P. Antonio Tataranni, MD
Journal: Diabetes Care
Diabetes Care 2003;26(12):3315–3319
https://doi.org/10.2337/diacare.26.12.3315
Published: 01 December 2003
View article titled, Plasma Adiponectin and Endogenous Glucose Production in Humans
Open the PDF for Plasma Adiponectin and Endogenous Glucose Production in Humans in another window
Journal Articles

Pramlintide Reduces Postprandial Glucose Excursions When Added to Regular Insulin or Insulin Lispro in Subjects With Type 1 Diabetes: A dose-timing study

Christian Weyer, MD, Alan Gottlieb, PA, Dennis D. Kim, MD, Karen Lutz, PHD, Sherwyn Schwartz, MD, Maria Gutierrez, MD, Yan Wang, PHD, James A. Ruggles, PHD, Orville G. Kolterman, MD, David G. Maggs, MD
Journal: Diabetes Care
Diabetes Care 2003;26(11):3074–3079
https://doi.org/10.2337/diacare.26.11.3074
Published: 01 November 2003
View article titled, Pramlintide Reduces Postprandial Glucose Excursions When Added to Regular Insulin or Insulin Lispro in Subjects With Type 1 Diabetes: <subtitle>A dose-timing study</subtitle>
Open the PDF for Pramlintide Reduces Postprandial Glucose Excursions When Added to Regular Insulin or Insulin Lispro in Subjects With Type 1 Diabetes: <subtitle>A dose-timing study</subtitle> in another window
Journal Articles

Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes: A 1-year randomized controlled trial

Priscilla A. Hollander, MD, Philip Levy, MD, Mark S. Fineman, BS, David G. Maggs, MD, Larry Z. Shen, PHD, Susan A. Strobel, PHD, Christian Weyer, MD, Orville G. Kolterman, MD
Journal: Diabetes Care
Diabetes Care 2003;26(3):784–790
https://doi.org/10.2337/diacare.26.3.784
Published: 01 March 2003
View article titled, Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes: <subtitle>A 1-year randomized controlled trial</subtitle>
Open the PDF for Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes: <subtitle>A 1-year randomized controlled trial</subtitle> in another window
Journal Articles

Impact of Pramlintide on Glucose Fluctuations and Postprandial Glucose, Glucagon, and Triglyceride Excursions Among Patients With Type 1 Diabetes Intensively Treated With Insulin Pumps

Claresa Levetan, MD, Laura L. Want, MS, Christian Weyer, MD, Susan A. Strobel, PHD, John Crean, PHD, Yan Wang, PHD, David G. Maggs, MD, Orville G. Kolterman, MD, Manju Chandran, MD, Sunder R. Mudaliar, MD, Robert R. Henry, MD
Journal: Diabetes Care
Diabetes Care 2003;26(1):1–8
https://doi.org/10.2337/diacare.26.1.1
Published: 01 January 2003
View article titled, Impact of Pramlintide on Glucose Fluctuations and Postprandial Glucose, Glucagon, and Triglyceride Excursions Among Patients With Type 1 Diabetes Intensively Treated With Insulin Pumps
Open the PDF for Impact of Pramlintide on Glucose Fluctuations and Postprandial Glucose, Glucagon, and Triglyceride Excursions Among Patients With Type 1 Diabetes Intensively Treated With Insulin Pumps in another window
Journal Articles

A Randomized Study and Open-Label Extension Evaluating the Long-Term Efficacy of Pramlintide as an Adjunct to Insulin Therapy in Type 1 Diabetes

Fred Whitehouse, MD, Davida F. Kruger, MSN, Mark Fineman, BS, Larry Shen, PHD, James A. Ruggles, PHD, David G. Maggs, MD, Christian Weyer, MD, Orville G. Kolterman, MD
Journal: Diabetes Care
Diabetes Care 2002;25(4):724–730
https://doi.org/10.2337/diacare.25.4.724
Published: 01 April 2002
View article titled, A Randomized Study and Open-Label Extension Evaluating the Long-Term Efficacy of Pramlintide as an Adjunct to Insulin Therapy in Type 1 Diabetes
Open the PDF for A Randomized Study and Open-Label Extension Evaluating the Long-Term Efficacy of Pramlintide as an Adjunct to Insulin Therapy in Type 1 Diabetes in another window
Journal Articles

Insulin Resistance and Insulin Secretory Dysfunction Are Independent Predictors of Worsening of Glucose Tolerance During Each Stage of Type 2 Diabetes Development

Christian Weyer, MD, P. Antonio Tataranni, MD, Clifton Bogardus, MD, Richard E. Pratley, MD
Journal: Diabetes Care
Diabetes Care 2001;24(1):89–94
https://doi.org/10.2337/diacare.24.1.89
Published: 01 January 2001
View article titled, Insulin Resistance and Insulin Secretory Dysfunction Are Independent Predictors of Worsening of Glucose Tolerance During Each Stage of Type 2 Diabetes Development
Open the PDF for Insulin Resistance and Insulin Secretory Dysfunction Are Independent Predictors of Worsening of Glucose Tolerance During Each Stage of Type 2 Diabetes Development in another window
Journal Articles

Time-Action Profiles of Novel Premixed Preparations of Insulin Lispro and NPL Insulin

Tim Heise, MD, Christian Weyer, MD, Andreas Serwas, MD, Sebastian Heinrichs, MD, Johannes Osinga, MD, Paris Roach, MD, Jim Woodworth, PHD, Uwe Gudat, MD, Lutz Heinemann, PHD
Journal: Diabetes Care
Diabetes Care 1998;21(5):800–803
https://doi.org/10.2337/diacare.21.5.800
Published: 01 May 1998
View article titled, Time-Action Profiles of Novel Premixed Preparations of Insulin Lispro and NPL Insulin
Open the PDF for Time-Action Profiles of Novel Premixed Preparations of Insulin Lispro and NPL Insulin in another window
Journal Articles

Insulin Aspart in a 30/70 Premixed Formulation: Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture

Christian Weyer, MD, Tim Heise, MD, Lutz Heinemann, PHD
Journal: Diabetes Care
Diabetes Care 1997;20(10):1612–1614
https://doi.org/10.2337/diacare.20.10.1612
Published: 01 October 1997
View article titled, Insulin Aspart in a 30/70 Premixed Formulation: Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture
Open the PDF for Insulin Aspart in a 30/70 Premixed Formulation: Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture in another window